FDA : Microbiological Quality Considerations in Non-sterile Drug Manufacturing Guidance for Industry (Draft)

FDA Guidance Documents

DRAFT GUIDANCE September 2021

Microbiological Quality Considerations in Non-sterile Drug Manufacturing Guidance for Industry (Draft)

Publisher / Origin: US FDA Website

EU GMP Guideline on the Quality of Water for Pharmaceutical use

WHO TRS 908 : Annex 7 Application of Hazard Analysis and Critical Control Point (HACCP) methodology to pharmaceuticals

EU GMP Annex 1: Manufacture of Sterile Medicinal Products (2022, Final)

WHO TRS 1033 : Annex 3 Good Manufacturing Practices: Water for Pharmaceutical use

WHO TRS 961 : Annex 2 WHO Good Practices for Pharmaceutical Microbiology Laboratories

WHO TRS 1019 : Annex 2 Guidelines on heating, ventilation and air-conditioning systems for non-sterile pharmaceutical products (Part2)

WHO TRS 1010 : Annex 8 Guidelines on heating, ventilation and air-conditioning systems for non-sterile pharmaceutical products (Part1)

Microbiology FDA 483 (Jubilant Radiopharmacies): The movement of first air in the ISO 5 area is blocked or disrupted

Jubilant DraxImage Radiopharmacies Inc.

Specifically, on 03/06/24, during the production of Gozetotide (Illucix) Cold Kit Lot# K-***, your firm's Pharmacy Manager was observed blocking first pass air in the ISO-5 *** flow hood. The following prescriptions were drawn from the cold kit and dispensed: RX*** (13.94 mCi) and RX*** (25.49 mCi).

May 27, 2024

Microbiology FDA 483 (Jubilant Radiopharmacies): Personnel were observed performing aseptic processing outside of an ISO 5 area

Jubilant DraxImage Radiopharmacies Inc.

Specifically, on 03/06/24, during the production of Gozetotide (Illucix) Cold Kit Lot# K-***, your firm's Pharmacy Manager was observed performing the following aseptic connections in the ISO-7 aseptic processing area: connecting the *** sterile *** to the Gallium Generator and connecting the Sterile *** to the Gallium Generator. The following prescriptions were drawn from the cold kit and dispensed: RX*** (13.94 mCi) and RX*** (25.49 mCi).

May 27, 2024

Microbiology FDA 483 (Eugia Pharma Specialities): Aseptic processing areas are deficient regarding the system for monitoring environmental conditions

Eugia Pharma Specialities Limited

Surface monitoring of the filling and stoppering machine is not performed in a timely manner following the completion of aseptic filling operations to ensure the data is representative of the environmental conditions at the time of filling. For example:

May 22, 2024

Microbiology FDA 483 (Eagl e Pharma Outsourcing LLC): Microbiological Contamination Prevention Issues

Eagle Pharma Outsourcing LLC

Your container closure integrity test for *** Injection (USP) ***mg/***ml is inadequate, The test used empty vials instead of fille vials. Microbial Challenge Study was conducted without a positive control. Dye ingress study was conducted using human eye detection with results "not detected" without specifying the limit of detection,

April 20, 2025

Microbiology FDA 483 (Jiangsu Hengrui Pharmceuticals): Container closure systems do not provide adequate protection against foreseeable external factors

Jiangsu Hengrui Pharmceuticals Co., Ltd

June 30, 2024

Microbiology FDA 483 (Jiangsu Hengrui Pharmceuticals): Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic and sterilization process

Jiangsu Hengrui Pharmceuticals Co., Ltd

Product contact equipment including *** stopper drums, *** were sterilized without outer wrapping and transferred from Grade A cart to Inside of the RABS without cover in Workshop *** Filling Room ***.